title: [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
abstract: The aim of the study was to evaluate the predictive and prognostic values of elevated serum levels of selected cancer markers (NSE, Cyfra 21-1, CEA, ferritin, free beta-hCG, LDH) in patients with inoperable non-small-cell lung cancer (NSCLC). We investigated a group of 79 patients (49 men and 30 women) with NSCLC. Multivariate regression analysis showed response in patients with NSE > 12.5 ng/ml (p = 0.002), good performance status (p = 0.007) and elderly patients (p = 0.005). However, elevated NSE adversely affected the prognosis. Median survival in patients with NSE < 12.5 ng/ml, 12.5-20.0 ng/ml and > 20.0 ng/ml was 13.3, 11.3 and 6.7 months, respectively (p = 0.004). The negative effect of elevated NSE was independent of the response category. Univariate regression analysis showed that the following factors had a significantly negative effect on the prognosis: performance status, stage IIIB or IV, weight loss of > 10%, NSE > 20 ng/ml, Cyfra 21-1 > 10 ng/ml, CEA > 3 ng/ml, ferritin ratio > 1 and LDH > 480 IU/l. Multivariate analysis showed an independent adverse prognostic effect of stage IIIB or IV and elevated ferritin.
authors.affiliation: m.zaleska@igichp.edu.pl
authors.forename: Monika
authors.initials: M
authors.lastname: Załeska
authors.forename: Monika
authors.initials: M
authors.lastname: Szturmowicz
authors.forename: Jacek
authors.initials: J
authors.lastname: Zych
authors.forename: Barbara
authors.initials: B
authors.lastname: Roszkowska-Sliz
authors.forename: Urszula
authors.initials: U
authors.lastname: Demkow
authors.forename: Renata
authors.initials: R
authors.lastname: Langfort
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Roszkowski-Sliz
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D053539:Keratin-19 / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011379:Prognosis; D012720:Severity of Illness Index; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018997:Chorionic Gonadotropin, beta Subunit, Human; D053539:Keratin-19; C102012:antigen CYFRA21.1; D005293:Ferritins; D007770:L-Lactate Dehydrogenase; D010751:Phosphopyruvate Hydratase